Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
LABFF Stock Price Chart
Explore Laboratorios Farmaceuticos Rovi, S.A. interactive price chart. Choose custom timeframes to analyze LABFF price movements and trends.
LABFF Company Profile
Discover essential business fundamentals and corporate details for Laboratorios Farmaceuticos Rovi, S.A. (LABFF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Apr 2021
Employees
2.20K
Website
https://www.rovi.esCEO
Juan Lopez-Belmonte Encina
Description
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
LABFF Financial Timeline
Browse a chronological timeline of Laboratorios Farmaceuticos Rovi, S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 5 Nov 2025
Earnings released on 24 Jul 2025
EPS came in at $0.50 , while revenue for the quarter reached $188.03M , beating expectations by +0.06%.
Earnings released on 8 May 2025
EPS came in at $0.39 , while revenue for the quarter reached $169.80M , beating expectations by +4.46%.
Earnings released on 25 Feb 2025
EPS came in at $1.87 , while revenue for the quarter reached $449.83M , beating expectations by +127.43%.
Dividend declared on 25 Feb 2025
A dividend of $1.09 per share was announced, adjusted to $1.09. The dividend was paid on 16 Jul 2025.
Earnings released on 7 Nov 2024
EPS came in at $1.42 , while revenue for the quarter reached $258.03M , beating expectations by +0.86%.
Earnings released on 31 Jul 2024
EPS came in at $0.59 , while revenue for the quarter reached $191.57M , beating expectations by +0.90%.
Earnings released on 8 May 2024
EPS came in at $0.31 , while revenue for the quarter reached $162.40M , missing expectations by -1.80%.
Earnings released on 27 Feb 2024
EPS came in at $1.09 , while revenue for the quarter reached $258.04M , beating expectations by +4.56%.
Dividend declared on 27 Feb 2024
A dividend of $1.19 per share was announced, adjusted to $1.29. The dividend was paid on 10 Jul 2024.
Earnings released on 30 Sept 2023
EPS came in at $1.03 , while revenue for the quarter reached $225.77M , beating expectations by +1.43%.
Dividend declared on 3 Jul 2023
A dividend of $1.41 per share was announced, adjusted to $1.52. The dividend was paid on 5 Jul 2023.
Earnings released on 30 Jun 2023
EPS came in at $0.39 , while revenue for the quarter reached $195.51M , beating expectations by +2.70%.
Earnings released on 31 Mar 2023
EPS came in at $0.97 , while revenue for the quarter reached $219.21M , beating expectations by +4.10%.
Earnings released on 21 Feb 2023
EPS came in at $1.58 , while revenue for the quarter reached $260.89M , beating expectations by +11.00%.
Earnings released on 4 Nov 2022
EPS came in at $0.78 , while revenue for the quarter reached $190.53M , beating expectations by +0.11%.
Earnings released on 27 Jul 2022
EPS came in at $0.54 , while revenue for the quarter reached $182.86M , beating expectations by +1.45%.
Dividend declared on 5 Jul 2022
A dividend of $0.98 per share was announced, adjusted to $1.12. The dividend was paid on 7 Jul 2022.
Earnings released on 11 May 2022
EPS came in at $1.09 , while revenue for the quarter reached $227.40M , beating expectations by +4.33%.
Earnings released on 23 Feb 2022
EPS came in at $1.12 surpassing the estimated $0.69 by +61.62%, while revenue for the quarter reached $209.94M , beating expectations by +7.72%.
Earnings released on 3 Nov 2021
EPS came in at $1.00 , while revenue for the quarter reached $201.32M .
Earnings released on 28 Jul 2021
EPS came in at $0.58 , while revenue for the quarter reached $189.24M .
Dividend declared on 5 Jul 2021
A dividend of $0.45 per share was announced, adjusted to $0.45. The dividend was paid on 7 Jul 2021.
Dividend declared on 2 Jul 2021
A dividend of $0.45 per share was announced, adjusted to $0.45. The dividend was paid on 7 Jul 2021.
Earnings released on 13 May 2021
EPS came in at $0.51 , while revenue for the quarter reached $153.55M .
Earnings released on 24 Feb 2021
EPS came in at $0.32 , while revenue for the quarter reached $144.49M .
Dividend declared on 17 Nov 2020
A dividend of $0.17 per share was announced, adjusted to $0.17. The dividend was paid on 19 Nov 2020.
Earnings released on 5 Nov 2020
EPS came in at $0.31 surpassing the estimated $0.18 by +72.22%, while revenue for the quarter reached $515.03M .
LABFF Stock Performance
Access detailed LABFF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.